Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Res Virol ; 145(5): 287-95, 1994.
Article in English | MEDLINE | ID: mdl-7839006

ABSTRACT

To study the antiviral efficacy of high doses of alpha 2b interferon (alpha 2b-IFN) for chronic hepatitis D treatment, we used polymerase-chain-reaction(PCR)-based semi-quantitative detection of HDV RNA. The semi-quantification method used was based on the appearance of a positive amplification signal as a function of the number of PCR cycles. By amplifying dilutions (10(-1)-10(-8)) of an HDV-positive woodchuck liver RNA, we confirmed that exponential amplification efficacy occurred at between 20 and 30 cycles. Positive signals were observed from dilution 10(-2) (gel electrophoresis after 20 cycles of PCR) to dilution 10(-7) (hybridization after 30 cycles of PCR). To characterize the HDV RNA level in sera of 8 patients treated with alpha 2b-IFN (10 MU/3 times a week) for 1 year, we extracted RNA from serum samples taken every 6 months. All samples were amplified in parallel for 20 and 30 PCR cycles. Analysis of HDV cDNA after ethidium bromide/agarose gel electrophoresis and after molecular hybridization (100 times more sensitive than gel analysis), enabled us to grade the signals observed from negative to positive as 1+, 2+, 3+ and 4+, with all results being positive. Three types of evolution of HDV viraemia were evidenced among the 8 treated patients. HDV replication continued to occur at a high level at the 6th and 12th month in 2 patient sera. For 2 other patients, an HDV RNA decrease or disappearance was evidenced in the serum at the 6th month; however, viral replication recurred at a higher level at the 12th month.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Hepatitis D/drug therapy , Interferon-alpha/therapeutic use , Polymerase Chain Reaction/methods , RNA, Viral/blood , Viremia/drug therapy , Adult , Base Sequence , Female , Hepatitis D/complications , Hepatitis Delta Virus/drug effects , Hepatitis, Chronic/drug therapy , Humans , Interferon alpha-2 , Liver Cirrhosis/complications , Male , Molecular Sequence Data , Recombinant Proteins , Virus Replication/drug effects
2.
Res Immunol ; 145(1): 17-27, 1994 Jan.
Article in English | MEDLINE | ID: mdl-8008965

ABSTRACT

Leishmania brasiliensis causes cutaneous leishmaniasis (CL) in humans. During this infection, a variety of inflammatory mediators are produced by T cells and monocytes/macrophages. In the present study, we analysed serum IgE levels and their correlation with in situ expression of the low affinity receptor for IgE (Fc epsilon RII/CD23) in patients infected with L. brasiliensis before and following therapy. These analyses were compared to in situ expression of tumour necrosis factor-alpha (TNF alpha), interleukin 3 (IL3), interferon-gamma (IFN gamma) and IL4. Disease-free individuals from the same endemic area sensitized with L. brasiliensis antigens were also included in this work. Our data indicate that during infection, serum levels of IgE and TNF alpha increased and correlated with elevated in situ expression of CD23, IL4 and TNF alpha mRNA. This expression disappeared following successful treatment, but persisted in patients resistant to anti-leishmania therapy. Patients resistant to therapy differed from other cases by a dramatic decrease in their in vivo expression of IFN gamma protein. Analysis of CD23 function in purified human monocytes indicated that this antigen mediates IgE/anti-IgE-dependent TNF alpha production. These data suggest a possible in vivo role of CD23 in acute immune responses in human CL.


Subject(s)
Antibodies, Protozoan/biosynthesis , Immunoglobulin E/biosynthesis , Leishmania braziliensis/immunology , Leishmaniasis, Cutaneous/immunology , Monocytes/immunology , Animals , Antiprotozoal Agents/administration & dosage , Antiprotozoal Agents/therapeutic use , Cytokines/immunology , Cytokines/metabolism , Gene Expression , Humans , Leishmaniasis, Cutaneous/drug therapy , Leishmaniasis, Cutaneous/metabolism , Protozoan Proteins/administration & dosage , RNA, Messenger/metabolism , Receptors, IgE/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...